Eli Lilly and Company (LLY)
| Market Cap | 961.99B |
| Revenue (ttm) | 59.42B |
| Net Income (ttm) | 18.41B |
| Shares Out | 895.38M |
| EPS (ttm) | 20.44 |
| PE Ratio | 52.56 |
| Forward PE | 34.32 |
| Dividend | $6.92 (0.64%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 1,043,935 |
| Open | 1,063.50 |
| Previous Close | 1,076.48 |
| Day's Range | 1,063.50 - 1,088.48 |
| 52-Week Range | 623.78 - 1,111.99 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 1,084.06 (+0.9%) |
| Earnings Date | Feb 5, 2026 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,084.06, which is an increase of 0.90% from the latest price.
News
Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma's 2026 Comeback
As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two names capture that shift better than Eli Lilly And Co (NYSE: LLY) and Novo Nord...
Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy
Abivax surged 1,470% YTD, driven by Obefazimod's clinical progress and takeover speculation, but I rate it Hold due to valuation risk. Obefazimod, a first-in-class oral therapy for ulcerative colitis,...
Eli Lilly Stock Falls. Novo Nordisk Got a Wegovy Weight-Loss Pill Approved in U.S.
Novo said it expects to launch the weight-loss pill in the U.S. in early January.
Our Top 10 High-Growth Dividend Stocks - December 2025
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
Graham: A.I. & Fed Top 2026 Themes, Top Picks in ANET, COHR & LLY
Andrew Graham says the next couple weeks will be hard to "separate the signal from the noise" in the A.I.-centric rebound due to low volume trading.
Mounjaro Maker Eli Lilly Improves In Quality As BofA Sees 'Room For Stock Upside' With $3 Billion In Sales By 2026
Weight loss drug Mounjaro's manufacturer, Eli Lilly and Co. (NYSE: LLY) has crossed a significant threshold in Benzinga Edge's Stock Rankings, moving into the top decile for quality this week. This im...
Thursday's Final Takeaways: Tech's Comeback & LLY Oral GLP-1 Drug
From Micron (MU) leading a strong comeback in tech, to Eli Lilly's (LLY) developments on an oral GLP-1 drug, Marley Kayden and Sam Vadas turn to headlines that caught their attention in Thursday's reb...
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound.
Eli Lilly on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company's injection Zepbound and Nov...
Obesity pill race heats up
CNBC's Annika Kim Constantino reports on Eli Lilly after the company said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from ...
Lose Weight on Zepbound, Keep It Off With Eli Lilly's New Pill? Data Say That Works.
Eli Lilly has a new pill, called orforglipron, it plans to launch next year.
After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss
The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity medicatio...
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
Eli Lilly said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking Wegovy and Zepbound injections in a late-stage trial...
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound Participants who switch...
Eli Lilly cuts price of diabetes, weight-loss drugs in Canada, Globe and Mail reports
Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada, the Globe and Mail reported on Wednesday, citing a note to pharmacies iss...
AbbVie, several other pharma companies near MFN deal with Trump, sources say
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...
Eli Lilly's stock has crushed Nvidia's in recent weeks. What history has to say about that.
“History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,” notes a DataTrek analyst — but there are some caveats
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
LLY Leading Weight Loss Trade, Hold Economic "Trickle Down Effect"
Tom Hulick sees Eli Lilly (LLY) leading the GLP-1 race and evolving healthcare race, noting the company's retatrutide drug as an example. He explains how the company's developments play into a larger ...
Lilly to participate in J.P. Morgan Healthcare Conference
INDIANAPOLIS , Dec. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the 44th Annual J.P. Morgan Healthcare Conference, Jan. 12-15, 2025.
Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars
Novo Nordisk A/S (NYSE: NVO) stock has plunged around 41% year to date, as per data from Benzinga Pro.
Eli Lilly's Obesity Drug Dominance Still Underpriced By Market, Bank of America Says
Eli Lilly & Co. (NYSE: LLY)'s dominance in obesity therapeutics looks increasingly difficult to challenge, and Bank of America believes the market is still underestimating just how much growth lies ah...
Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)
Eli Lilly's recent long streak of correction for nine trading days calls for a look at the stock even as it has stabilised now. It's explained by stretched valuations and also the lowering of prices o...
Eli Lilly: The Right Long-Term Strategy
Eli Lilly is positioned for a secular growth trajectory, leveraging its duopoly in diabetes and obesity therapies while investing heavily in pipeline diversification. LLY faces intensifying competitio...
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated disease In all patients, the imlunestrant plus abemacicl...